Literature DB >> 16487243

The local immune response in ulcerative lesions of Buruli disease.

A E Kiszewski1, E Becerril, L D Aguilar, I T A Kader, W Myers, F Portaels, R Hernàndez Pando.   

Abstract

Buruli disease (BU) is a progressive necrotic and ulcerative disease of the skin and subcutaneous tissue caused by Mycobacterium ulcerans. BU is considered the third most common mycobacterial disease after tuberculosis and leprosy. Three clinical stages of the cutaneous lesions have been described in BU: pre-ulcerative, ulcerative and healed lesions. In this study we used immunohistochemistry and automated morphometry to determine the percentage of macrophages and of CD4/CD8 lymphocytes and their expression of interferon (IFN)-gamma, interleukin (IL)-10, tumour necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta. Expression of these cytokines was correlated with the inflammatory response evaluated by histopathology. All the studied BU ulcerative cases showed extensive necrosis and chronic inflammation. The most important feature was the presence or absence of granulomas co-existing with a mixed pro-inflammatory/anti-inflammatory cytokine balance. When granulomas were present significantly higher expression of IFN-gamma was seen, whereas in ulcerative lesions without granulomas there was increased expression of IL-10 and significantly higher bacillary counts. These features correlated with the chronicity of the lesions; longer-lasting lesions showed granulomas. Thus, granulomas were absent from relatively early ulcerative lesions, which contained more bacilli and little IFN-gamma, suggesting that at this stage of the disease strong suppression of the protective cellular immune response facilitates proliferation of bacilli.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487243      PMCID: PMC1809619          DOI: 10.1111/j.1365-2249.2006.03020.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans.

Authors:  Travis M Gooding; Andrew S Kemp; Roy M Robins-Browne; May Smith; Paul D R Johnson
Journal:  Clin Infect Dis       Date:  2003-04-03       Impact factor: 9.079

Review 2.  Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection.

Authors:  J Hayman
Journal:  J Clin Pathol       Date:  1993-01       Impact factor: 3.411

3.  Human Mycobacterium ulcerans infections developing at sites of trauma to skin.

Authors:  W M Meyers; W M Shelly; D H Connor; E K Meyers
Journal:  Am J Trop Med Hyg       Date:  1974-09       Impact factor: 2.345

4.  Aquatic insects as a vector for Mycobacterium ulcerans.

Authors:  Laurent Marsollier; Raymond Robert; Jacques Aubry; Jean-Paul Saint André; Henri Kouakou; Pierre Legras; Anne-Lise Manceau; Chetaou Mahaza; Bernard Carbonnelle
Journal:  Appl Environ Microbiol       Date:  2002-09       Impact factor: 4.792

5.  Defining protective responses to pathogens: cytokine profiles in leprosy lesions.

Authors:  M Yamamura; K Uyemura; R J Deans; K Weinberg; T H Rea; B R Bloom; R L Modlin
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

6.  Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans.

Authors:  Timothy P Stinear; Armand Mve-Obiang; Pamela L C Small; Wafa Frigui; Melinda J Pryor; Roland Brosch; Grant A Jenkin; Paul D R Johnson; John K Davies; Richard E Lee; Sarojini Adusumilli; Thierry Garnier; Stephen F Haydock; Peter F Leadlay; Stewart T Cole
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-21       Impact factor: 11.205

Review 7.  Immunology of tuberculosis and implications in vaccine development.

Authors:  JoAnne L Flynn
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

8.  Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence.

Authors:  Armand Mve-Obiang; Richard E Lee; Françoise Portaels; P L C Small
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

9.  Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease.

Authors:  Ghislaine Prévot; Eliane Bourreau; Herve Pascalis; Roger Pradinaud; Audrey Tanghe; Kris Huygen; Pascal Launois
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  Histopathologic features of Mycobacterium ulcerans infection.

Authors:  Jeannette Guarner; Jeanine Bartlett; Ellen A Spotts Whitney; Pratima L Raghunathan; Ymkje Stienstra; Kwame Asamoa; Samuel Etuaful; Erasmus Klutse; Eric Quarshie; Tjip S van der Werf; Winette T A van der Graaf; C Harold King; David A Ashford
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883

View more
  26 in total

Review 1.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

2.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

3.  Mice Deficient in Angiopoietin-like Protein 2 (Angptl2) Gene Show Increased Susceptibility to Bacterial Infection Due to Attenuated Macrophage Activity.

Authors:  Masaki Yugami; Haruki Odagiri; Motoyoshi Endo; Hiroyasu Tsutsuki; Shigemoto Fujii; Tsuyoshi Kadomatsu; Tetsuro Masuda; Keishi Miyata; Kazutoyo Terada; Hironori Tanoue; Hitoshi Ito; Jun Morinaga; Haruki Horiguchi; Taichi Sugizaki; Takaaki Akaike; Tomomi Gotoh; Toshiyuki Takai; Tomohiro Sawa; Hiroshi Mizuta; Yuichi Oike
Journal:  J Biol Chem       Date:  2016-07-11       Impact factor: 5.157

4.  Macrophage-Microglia Networks Drive M1 Microglia Polarization After Mycobacterium Infection.

Authors:  Yongwei Qin; Xiaolei Sun; Xiaoyi Shao; Chun Cheng; Jinrong Feng; Wei Sun; Delin Gu; Wei Liu; Feifan Xu; Yinong Duan
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

5.  Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.

Authors:  Egídio Torrado; Alexandra G Fraga; António G Castro; Pieter Stragier; Wayne M Meyers; Françoise Portaels; Manuel T Silva; Jorge Pedrosa
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

6.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

Review 7.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

8.  Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas.

Authors:  R Hurtado Ortiz; D Aguilar Leon; H Orozco Estevez; A Martin; J Luna Herrera; L Flores Romo; F Portaels; R Hernandez Pando
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

9.  Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.

Authors:  Egídio Torrado; Sarojini Adusumilli; Alexandra G Fraga; Pamela L C Small; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

10.  Systemic and local interferon-gamma production following Mycobacterium ulcerans infection.

Authors:  H S Schipper; B Rutgers; M G Huitema; S N Etuaful; B D Westenbrink; P C Limburg; W Timens; T S van der Werf
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.